(Post-pandemic Era)-Global Peptides and Heparin Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
- Report Code : XYZ2157189
- Published On: Dec, 2020
- Category : Medical Devices
- Pages : 119
-
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Research team published a report for global Peptides and Heparin market in this environment.
In terms of revenue, this research report indicated that the global Peptides and Heparin market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Peptides and Heparin industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Cipla Ltd. aims at producing XX Peptides and Heparin in 2020, with XX % production to take place in global market, Emcure Pharmaceuticals Pvt. Ltd. accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Peptides and Heparin Market Include by
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Peptides and Heparin Market
Cipla Ltd.
Emcure Pharmaceuticals Pvt. Ltd.
Gland Pharma Limited
Troikaa Pharmaceuticals Ltd.
Biological E Limited
Bharat Biotech
Samarth Life Sciences Pvt. Ltd.
VHB Life Sciences Limited
Celon Laboratories Pvt. Ltd.
United Biotech (P) Limited
Biocon Limited
Sun Pharmaceutical Industries Ltd.
Wockhardt Ltd.
Major Type of Peptides and Heparin Covered in Research report:
Insulin
Teriparatide
Liraglutide
Leuprolide
Leuprolide
Exenatide
Calcitonin
Enaxaparin Sodium
Heparin Sodium
Application Segments Covered in Research report:
Diabetes
Infectious Diseases
Cancer
Osteoporosis
For any other requirements, please feel free to contact us and we will provide you customized report.
-
With tables and figures helping analyze worldwide (Post pandemic Era) Global Peptides and Heparin market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Global Peptides and Heparin Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope1.1 Product Details and Introduction
1.1.1 Insulin -Product Introduction and Major Manufacturers
1.1.2 Teriparatide -Product Introduction and Major Manufacturers
1.1.3 Liraglutide -Product Introduction and Major Manufacturers
1.1.4 Leuprolide -Product Introduction and Major Manufacturers
1.1.5 Leuprolide -Product Introduction and Major Manufacturers
1.1.6 Exenatide -Product Introduction and Major Manufacturers
1.1.7 Calcitonin -Product Introduction and Major Manufacturers
1.1.8 Enaxaparin Sodium -Product Introduction and Major Manufacturers
1.1.9 Heparin Sodium -Product Introduction and Major Manufacturers1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Peptides and Heparin Market Assessment, by Segmentation2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis3.1 China Peptides and Heparin Market
3.1.1 Top Companies leading Peptides and Heparin Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Peptides and Heparin Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)3.2 EU Peptides and Heparin Market
3.2.1 Top Companies leading Peptides and Heparin Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Peptides and Heparin Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)3.3 USA Peptides and Heparin Market
3.3.1 Top Companies leading Peptides and Heparin Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Peptides and Heparin Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)3.4 Japan Peptides and Heparin Market
3.4.1 Top Companies leading Peptides and Heparin Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Peptides and Heparin Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)3.5 India Peptides and Heparin Market
3.5.1 Top Companies leading Peptides and Heparin Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Peptides and Heparin Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)3.6 Southeast Asia Peptides and Heparin Market
3.6.1 Top Companies leading Peptides and Heparin Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Peptides and Heparin Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Peptides and Heparin Market
3.7.1 Top Companies leading Peptides and Heparin Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Peptides and Heparin Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)4.1 Peptides and Heparin Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream4.2 COVID-19 Impact on Peptides and Heparin Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)5.1 Global Peptides and Heparin Sales and Growth Rate (2021-2026)
5.2 Global Peptides and Heparin Sales Value and Growth Rate (2021-2026)
6 Peptides and Heparin Competitive Analysis6.1 Cipla Ltd.
6.1.1 Cipla Ltd. Company Profiles
6.1.2 Cipla Ltd. Product Introduction
6.1.3 Cipla Ltd. Peptides and Heparin Production, Revenue (2015-2020)
6.1.4 SWOT Analysis6.2 Emcure Pharmaceuticals Pvt. Ltd.
6.2.1 Emcure Pharmaceuticals Pvt. Ltd. Company Profiles
6.2.2 Emcure Pharmaceuticals Pvt. Ltd. Product Introduction
6.2.3 Emcure Pharmaceuticals Pvt. Ltd. Peptides and Heparin Production, Revenue (2015-2020)
6.2.4 SWOT Analysis6.3 Gland Pharma Limited
6.3.1 Gland Pharma Limited Company Profiles
6.3.2 Gland Pharma Limited Product Introduction
6.3.3 Gland Pharma Limited Peptides and Heparin Production, Revenue (2015-2020)
6.3.4 SWOT Analysis6.4 Troikaa Pharmaceuticals Ltd.
6.4.1 Troikaa Pharmaceuticals Ltd. Company Profiles
6.4.2 Troikaa Pharmaceuticals Ltd. Product Introduction
6.4.3 Troikaa Pharmaceuticals Ltd. Peptides and Heparin Production, Revenue (2015-2020)
6.4.4 SWOT Analysis6.5 Biological E Limited
6.5.1 Biological E Limited Company Profiles
6.5.2 Biological E Limited Product Introduction
6.5.3 Biological E Limited Peptides and Heparin Production, Revenue (2015-2020)
6.5.4 SWOT Analysis6.6 Bharat Biotech
6.6.1 Bharat Biotech Company Profiles
6.6.2 Bharat Biotech Product Introduction
6.6.3 Bharat Biotech Peptides and Heparin Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Samarth Life Sciences Pvt. Ltd.
6.7.1 Samarth Life Sciences Pvt. Ltd. Company Profiles
6.7.2 Samarth Life Sciences Pvt. Ltd. Product Introduction
6.7.3 Samarth Life Sciences Pvt. Ltd. Peptides and Heparin Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 VHB Life Sciences Limited
6.8.1 VHB Life Sciences Limited Company Profiles
6.8.2 VHB Life Sciences Limited Product Introduction
6.8.3 VHB Life Sciences Limited Peptides and Heparin Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Celon Laboratories Pvt. Ltd.
6.9.1 Celon Laboratories Pvt. Ltd. Company Profiles
6.9.2 Celon Laboratories Pvt. Ltd. Product Introduction
6.9.3 Celon Laboratories Pvt. Ltd. Peptides and Heparin Production, Revenue (2015-2020)
6.9.4 SWOT Analysis6.10 United Biotech (P) Limited
6.10.1 United Biotech (P) Limited Company Profiles
6.10.2 United Biotech (P) Limited Product Introduction
6.10.3 United Biotech (P) Limited Peptides and Heparin Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
6.11 Biocon Limited
6.12 Sun Pharmaceutical Industries Ltd.
6.13 Wockhardt Ltd.
7 Conclusion
-
The (Post pandemic Era) Global Peptides and Heparin Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
Recognize the areas along the (Post pandemic Era) Global Peptides and Heparin Market's value chain where players are generating value. To get a complete picture, kindly read the entire report.
(Post pandemic Era) Global Peptides and Heparin has a wide range of applications, including
In recent years, the (Post pandemic Era) Global Peptides and Heparin Market has grown at an incredible rate. From 2024 to 2029, the market is expected to grow at a CAGR of yy%.
The (Post pandemic Era) Global Peptides and Heparin Market research study aids businesses in strategic planning so that they may realize and gain business value from their growth strategies.
In this highly competitive and rapidly evolving (Post pandemic Era) Global Peptides and Heparin Industry, top strategic priorities such as innovation, diversification, and M&A would remain consistent.
